Human Monoclonal Antibodies That Target Blood-Stage RH5 for Malaria Control

Commercially available antibodies that target Plasmodium falciparum—the parasite responsible for most cases of malaria in humans—are primarily directed against the circumsporozoite protein (CSP). While CSP is present prior to blood-stage infection, antibodies specific to proteins in the blood stage may aid in preventing and controlling parasitic infection.